Duloxetine in the Treatment of Binge Eating Disorder with Depressive Disorders: A Placebo-Controlled Trial

作者：Guerdjikova Anna I^*; McElroy Susan L; Winstanley Erin L; Nelson Eric B; Mori Nicole; McCoy Jessica; Keck Paul E Jr; Hudson James I

来源：International Journal of Eating Disorders, 2012, 45(2): 281-289.

DOI：10.1002/eat.20946

• duloxetine
• binge eating disorder
• depression
• obesity
• longitudinal analysis

Objective: This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. %26lt;br%26gt;Method: In this 12-week, double-blind, placebo-controlled trial, 40 pati-ents with Diagnostic and Statistical Manual of Mental Disorders-IV-TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency. %26lt;br%26gt;Results: In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression-Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups. %26lt;br%26gt;Discussion: Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo-controlled trials.

• 出版日期2012-3